Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
SAN DIEGO–(BUSINESS WIRE)–May 13, 2014–
Liquid Grids®, a Precision Marketing Platform marketing for the Healthcare Industry, has recently completed a Series A investment round led by Miramar Digital Ventures (MDV). The company has also appointed Daniel M. Bradbury, former CEO of Amylin Pharmaceuticals, as new Chairman of the Board and added Sherman Atkinson as a Director.
Through its proprietary analytics engine Liquid Grids has aggregated and analyzed over 1 Billion healthcare conversations by over 125 million unique healthcare consumers. The company identifies disease-specific personas, which are scaled to deliver highly targeted, multi-channel advertising campaigns. “Closing this round of investment is fueling a rapid scaling of the opportunity we have cornered in the market and to extend our reach across the industry,” says Malcolm Bohm, CEO of Liquid Grids.
“Traditional Direct to Consumer advertising is inefficient and delivers irrelevant information to most people who receive it,” said Daniel M. Bradbury, the newly appointed Chairman of the Board for Liquid Grids. “Liquid Grids is the only company leveraging the power of the social networks to turn DTC on its head and deliver real value to the healthcare industry’s marketing spend.”
“Digital advertising within the health care space is growing exponentially, and Liquid Grids is leading the industry with its powerful analytics and targeted buyer personas and inbound strategies,” said Sherman Atkinson, Managing Director of Miramar Digital Ventures. “We are very excited to have added Liquid Grids to the Miramar Digital Ventures portfolio.”
About Liquid Grids®
Liquid Grids®, the pioneer in Direct to Persona Marketing®, is servicing companies across the healthcare spectrum to deliver the most effective contribution to digital and social media marketing and advertising campaigns. By providing the most advanced and predictive intelligence available about healthcare consumers, the platform drives insightful marketing strategies that change the way the healthcare industry interacts with online health communities. Learn more at www.liquidgrids.com.
About Daniel M. Bradbury, Chairman of the Board
Daniel M. Bradbury has served as a director of Geron since September 2012. He also serves as a member of the boards of directors of Illumina, Inc., a manufacturer of life-science tools and integrated systems for the analysis of genetic variation and biological function; Corcept Therapeutics, a company focused on the discovery and development of drugs that regulate the effects of cortisol; BioCon Ltd., a company focused on reducing therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases; and BioMed Realty, a real estate investment trust focused on providing real estate to the life science industry, as well as being a member of the board of trustees of the Keck Graduate Institute. He also serves on the University of California San Diego, Rady School of Management’s Advisory Council, the University of Miami’s Innovation Corporate Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders, from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin’s President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, a pharmaceutical company, holding a number of sales and marketing positions. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
About Miramar Digital Ventures
Miramar Digital Ventures (MDV) is a seed and early-stage fund uniquely focused on investing in the most promising founders and market disruptive ideas. MDV, located in Newport Beach, California and Park City, Utah, invests in companies across North America as well as Hong Kong and mainland China.